DB
CYTK icon

Dmitry Balyasny’s Cytokinetics CYTK Stock Holding History

Dmitry Balyasny’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.65M Sell
19,400
-86,200
-82% -$6.19M ﹤0.01% 1921
2026
Q1 		$6.96M Sell
105,600
-252,900
-71% -$16.1M 0.01% 1208
2025
Q4 		$22.8M Sell
358,500
-2,100
-0.6% -$131K 0.03% 645
2025
Q3 		$19.8M Buy
+360,600
New +$14.9M 0.03% 722
2024
Q4 		– Sell
-4,700
Closed -$248K – 2842
2024
Q3 		$248K Sell
4,700
-196,400
-98% -$10.9M ﹤0.01% 2503
2024
Q2 		$10.9M Sell
201,100
-50,000
-20% -$3.02M 0.02% 844
2024
Q1 		$17.6M Sell
251,100
-89,000
-26% -$6.88M 0.03% 672
2023
Q4 		$28.4M Buy
340,100
+294,800
+651% +$10.7M 0.05% 474
2023
Q3 		$1.33M Buy
+45,300
New +$1.51M ﹤0.01% 1494
2020
Q4 		– Sell
-40,000
Closed -$866K – 1395
2020
Q3 		$866K Buy
+40,000
New +$936K 0.01% 1026

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dmitry Balyasny's CYTK Position: Q2 2026 in Review

Dmitry Balyasny reduced its Cytokinetics (CYTK) stake by 28% in Q2 2026, selling an estimated $20.2M and leaving 711,676 shares worth $60.6M. The position accounts for 0.08% of the portfolio, ranked #311.

Dmitry Balyasny first reported a position in CYTK in Q4 2015 and has held it in 22 quarters since. The position peaked at $65.4M in Q1 2026. 479 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Dmitry Balyasny held 711,676 shares of Cytokinetics worth $60.6M as of Q2 2026.
  • Dmitry Balyasny sold 280,869 Cytokinetics shares in Q2 2026, an estimated $20.2M.
  • Cytokinetics made up 0.08% of Dmitry Balyasny's portfolio in Q2 2026, its #311 holding.
  • Dmitry Balyasny first reported a position in Cytokinetics in Q4 2015 and has held it in 22 quarters since.
  • Dmitry Balyasny's Cytokinetics position peaked at $65.4M in Q1 2026.
  • 479 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.